Please provide your email address to receive an email when new articles are posted on . Mitsubishi Tanabe Pharma America and Aquestive Therapeutics announced a licensing and supply deal for U.S.
MIAMI, Oct. 2, 2012 /PRNewswire/ -- Fuisz Pharma announced today a patented film formulation for enhanced drug delivery performance. The seminal patent for this technology issued as United States ...
In the Complete Response Letter (CRL), the FDA noted that it was unable to approve the application in its present form, however the Agency did not request additional clinical studies. Following a ...
VANCOUVER, BC / ACCESS Newswire / July 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
Credit: Shutterstock. Libervant is a buccally administered soluble film of diazepam. The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for ...
The US Food and Drug Administration (FDA) has approved an oral film formulation of riluzole (Exservan, Aquestive Therapeutics) for the treatment of patients with amyotrophic lateral sclerosis (ALS), ...
Thirty months after being knocked back by the FDA, IntelGenx has filed its response to the complete response letter to advance its push to bring its oral disintegrating film migraine drug to the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results